Pharmacogenomic prescribing opportunities in percutaneous coronary intervention and bone marrow transplant patients.
Lindsay RatnerJing 'Daisy' ZhuMegan N GowerTejendra PatelJordan A MillerAmber CiprianiGeorge A StoufferDaniel J CronaAnd Craig R LeePublished in: Pharmacogenomics (2022)
Aim: To evaluate the potential impact of preemptive multigene pharmacogenomic (PGx) testing on medication prescribing in real-world clinical settings. Patients & methods: Prescription frequencies for 65 medications with actionable PGx recommendations were collected in 215 percutaneous coronary intervention (PCI) and 131 allogeneic hematopoietic cell transplant (allo-HCT) patients. A simulation projected the number of PGx-guided prescribing opportunities. Results: In PCI and allo-HCT patients, respectively, 66.5 and 90.1% were prescribed at least one medication with actionable PGx prescribing recommendations. Simulations projected 26.5 and 41.2 total PGx-guided prescribing opportunities per 100 PCI and allo-HCT patients, respectively, if multigene PGx results were available. Conclusion: A multigene PGx testing strategy offers potential to optimize medication prescribing beyond clopidogrel and tacrolimus in PCI and allo-HCT patients.
Keyphrases
- end stage renal disease
- percutaneous coronary intervention
- bone marrow
- chronic kidney disease
- newly diagnosed
- primary care
- prognostic factors
- heart failure
- emergency department
- mesenchymal stem cells
- atrial fibrillation
- risk assessment
- single cell
- coronary artery bypass grafting
- cell death
- human health
- pi k akt
- coronary artery bypass